BSW Wealth Partners Acquires 76 Shares of Stryker Co. (NYSE:SYK)

BSW Wealth Partners lifted its holdings in shares of Stryker Co. (NYSE:SYK) by 5.6% in the fourth quarter, according to its most recent filing with the SEC. The firm owned 1,431 shares of the medical technology company’s stock after acquiring an additional 76 shares during the period. BSW Wealth Partners’ holdings in Stryker were worth $515,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Capital Planning LLC increased its position in shares of Stryker by 3.6% during the 4th quarter. Capital Planning LLC now owns 841 shares of the medical technology company’s stock worth $304,000 after purchasing an additional 29 shares in the last quarter. Alhambra Investment Management LLC grew its stake in Stryker by 1.5% during the fourth quarter. Alhambra Investment Management LLC now owns 1,997 shares of the medical technology company’s stock worth $719,000 after buying an additional 29 shares during the last quarter. Avestar Capital LLC increased its holdings in shares of Stryker by 1.1% during the third quarter. Avestar Capital LLC now owns 2,948 shares of the medical technology company’s stock worth $1,065,000 after buying an additional 31 shares in the last quarter. Union Savings Bank raised its stake in shares of Stryker by 1.0% in the fourth quarter. Union Savings Bank now owns 3,162 shares of the medical technology company’s stock valued at $1,138,000 after acquiring an additional 31 shares during the last quarter. Finally, Patrick M Sweeney & Associates Inc. grew its position in Stryker by 1.5% during the 3rd quarter. Patrick M Sweeney & Associates Inc. now owns 2,194 shares of the medical technology company’s stock worth $793,000 after acquiring an additional 32 shares during the last quarter. Institutional investors own 77.09% of the company’s stock.

Insider Buying and Selling at Stryker

In other news, CEO Kevin Lobo sold 57,313 shares of the business’s stock in a transaction on Thursday, November 7th. The shares were sold at an average price of $368.70, for a total value of $21,131,303.10. Following the sale, the chief executive officer now owns 100,027 shares of the company’s stock, valued at $36,879,954.90. The trade was a 36.43 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Company insiders own 5.90% of the company’s stock.

Stryker Price Performance

SYK opened at $390.98 on Thursday. The company has a fifty day simple moving average of $376.44 and a 200 day simple moving average of $361.98. The company has a quick ratio of 1.22, a current ratio of 1.91 and a debt-to-equity ratio of 0.66. The stock has a market cap of $149.05 billion, a P/E ratio of 41.91, a P/E/G ratio of 2.68 and a beta of 0.95. Stryker Co. has a 12 month low of $314.05 and a 12 month high of $406.19.

Stryker (NYSE:SYK) last announced its earnings results on Tuesday, January 28th. The medical technology company reported $4.01 EPS for the quarter, topping the consensus estimate of $3.87 by $0.14. Stryker had a net margin of 16.34% and a return on equity of 23.07%. During the same quarter in the prior year, the company posted $3.46 EPS. On average, research analysts expect that Stryker Co. will post 12.06 EPS for the current year.

Stryker Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, January 31st. Shareholders of record on Tuesday, December 31st will be issued a dividend of $0.84 per share. This represents a $3.36 dividend on an annualized basis and a yield of 0.86%. The ex-dividend date of this dividend is Tuesday, December 31st. This is a boost from Stryker’s previous quarterly dividend of $0.80. Stryker’s dividend payout ratio is 36.01%.

Wall Street Analysts Forecast Growth

SYK has been the topic of a number of recent analyst reports. Needham & Company LLC reissued a “buy” rating and issued a $442.00 price objective on shares of Stryker in a research note on Wednesday. BTIG Research increased their price objective on shares of Stryker from $383.00 to $394.00 and gave the stock a “buy” rating in a report on Wednesday, October 30th. UBS Group boosted their target price on shares of Stryker from $366.00 to $370.00 and gave the stock a “neutral” rating in a research note on Wednesday, October 30th. Morgan Stanley raised shares of Stryker from an “equal weight” rating to an “overweight” rating and increased their price target for the company from $370.00 to $445.00 in a research note on Monday, December 2nd. Finally, Canaccord Genuity Group boosted their price objective on shares of Stryker from $420.00 to $435.00 and gave the stock a “buy” rating in a research report on Wednesday. Five research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $413.45.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.